Nimmune Biopharma, Inc.

BLACKSBURG, Va.--( BUSINESS WIRE )--NImmune Biopharma ("NImmune”), a Phase 3 precision inflammation & immunology (I&I) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics starting with ulcerative colitis and Crohn’s disease, today announced that Founder and CEO Josep Bassaganya-Riera will participate in the UBS Virtual Biotechnology Private Company Symposium on September 18-19 th , 2024. The symposium provides the opportunity for leading investors to meet one-on-one and in small groups with participating companies and innovators in biotechnology. About NImmune Biopharma NImmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. The lead product candidate from NImmune’s discovery platform is omilancor, a wholly-owned oral, once-daily, gut-restricted, first-in-class therapeutic currently in Phase 3 development, which targets LANCL2 for Ulcerative Colitis and Crohn’s disease. Phase 2 proof-of-concept data for omilancor show potential best in class efficacy and safety. For more information, please visit www.NIMMUNEBIO.COM or contact media@nimmunebio.com .

The deal will aid NImmune in the development of both animal and computational models for inflammatory and autoimmune diseases. Credit: sergey kolesnikov/Shutterstock. NImmune Biopharma has entered a research partnership with BioTherapeutics, aimed at propelling the development of new precision medicines in the field of inflammation and immunology. The deal will enhance NImmune’s capabilities in precision immunology by leveraging BioTherapeutics’ extensive preclinical services and regulatory expertise. NImmune will benefit from BioTherapeutics’ animal models, including pig models for inflammatory bowel disease, pharmacokinetics/pharmacodynamics analysis capabilities and specialised regulatory infrastructure for product testing. The deal will also aid in mechanism of action validation studies and the development of both animal and computational models of autoimmune and inflammatory diseases. BioTherapeutics chief scientific officer Dr Raquel Hontecillas stated: “We are excited to collaborate across teams in support of the development of much-needed therapeutics by providing our highly sophisticated computational and preclinical services, including our proprietary efficacy animal models of autoimmune and inflammatory disease. See Also: Investment opportunities in atopic dermatitis may drive innovation EC approves Merck’s Keytruda-Padcev combo for urothelial cancer “The unique drug development ecosystem created here in Blacksburg enables and equips our organisations to develop safer and more effective therapeutics at an increasingly efficient and accelerated pace.” The partnership with BioTherapeutics adds to NImmune’s existing research and development (R&D) collaboration with the NIMML Institute. Together, they will form a scientific innovation ecosystem that enables transdisciplinary teams to collaborate from discovery through various development phases. This ecosystem has already yielded significant clinical and commercial success, as evidenced by the development of NX-13 and its subsequent acquisition by AbbVie . NImmune founder and CEO Dr Josep Bassaganya-Riera stated: “The collaboration with BioTherapeutics is a crucial extension of NImmune’s innovative R&D ecosystem that is enabling our team to create safer and more effective immunoregulatory therapeutics that address the unmet clinical needs of patients with inflammatory and autoimmune diseases. “Through NImmune’s strategic partnerships with both the NIMML Institute and BioTherapeutics, we have created a best-in-class scientific ecosystem capable of accelerating the pipeline — from AI-enabled target discovery and validation using the TITAN-X platform to preclinical animal modelling to clinical testing and ultimately commercialisation.”

The biologic therapy is created to deliver the radioisotope 225Ac to tumours expressing the DLL3 protein. Credit: Kateryna Kon/Shutterstock. The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a treatment aimed at neuroendocrine carcinoma. The biologic therapy is created to deliver the radioisotope Actinium-225 (225Ac) to tumours expressing the DLL3 protein. This protein is found on the neuroendocrine tumours’ surface but is rarely expressed on the normal cells or tissues’ surface. The ODD status is expected to provide Abdera with benefits including tax credits, user fee exemptions and a potential seven years of market exclusivity post-approval. The company is set to commence a first-in-human Phase I clinical trial of ABD-147 in 2024. See Also: FDA grants ODD to Abdera’s neuroendocrine carcinoma treatment NImmune and BioTherapeutics partner on precision medicine development The trial will involve patients with small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) who have previously undergone platinum-based therapy. ABD-147’s targeted approach utilises Actinium-225, a potent alpha-emitting radioisotope, to selectively attack solid tumours expressing the delta-like ligand 3 (DLL3) with high affinity. Abdera Therapeutics chief medical officer Philippe Bishop stated: “Neuroendocrine carcinomas, including SCLC and LCNEC, are aggressive and challenging to treat effectively with current systemic therapies. “By delivering a potent radioisotope to neuroendocrine tumours expressing DLL3 with custom-engineered PK properties, we believe ABD-147 has the potential to become a best-in-class DLL3-targeting treatment for aggressive neuroendocrine tumours. “Along with FDA recently granting fast track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy, this orphan drug designation for neuroendocrine carcinoma further underscores the potential of ABD 147 development to offer a significant advantage beyond approved drugs.” This content was updated on 25 January 2024